s6y ARGOS THERAPEUTICS INC CORRESP

ARGOS THERAPEUTICS INC CORRESP, filed Jan 22, 2018: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

 

January 22, 2018

 

Via EDGAR

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: Argos Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-222414
Request for Acceleration

 

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Argos Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-222414) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on January 24, 2018, or as soon thereafter as practicable.

 

Very truly yours,

 

Argos Therapeutics, Inc.

 

By: /s/ Lori R. Harrelson  
Name: Lori R. Harrelson  
Title: Vice President of Finance